Phaseline

Companies › PleoPharma

PleoPharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Psychiatry; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PP-01
Cannabinoid-1 (CB1) partial agonist / GABAergic modulator
CNR1, GABAPhase 3Cannabis WithdrawalJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07644052PP-01Phase 3Cannabis WithdrawalPsychiatryJun 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

CNR1 (1) GABA (1)

Companies with the same targets

Jazz Pharmaceuticals IGC Pharma Sinfatin Zynerba Pharmaceuticals Skye Bioscience Laboratorio Elea Phoenix Bazelet Nehushtan Incannex Healthcare Vertanical Alasht Pharmed

Companies built like this

Bazelet Nehushtan Gedeon Richter Cybin IRL Beijing Union Pharmaceutical Factory Newron Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.